Sanofi: cancels collaboration agreement on Zynquista
(CercleFinance.com) - Sanofi announces that, based on initial results for three Phase III trials of the InSynchrony Clinical Program dedicated to Zynquista, it has notified Lexicon of the termination of the collaboration agreement in the diabetes 1 and 2 progrms.
At present, all ongoing phase III trials are continuing and no immediate changes are expected. Sanofi wants to work with Lexicon to ensure the transfer of responsibilities relating to studies in optimal possible conditions.
The French healthcare giant is also committed to working with and supporting the investigators and patients included in the ongoing phase III studies, pending the definition of the terms of this transfer with Lexicon.
Copyright (c) 2019 CercleFinance.com. All rights reserved.
At present, all ongoing phase III trials are continuing and no immediate changes are expected. Sanofi wants to work with Lexicon to ensure the transfer of responsibilities relating to studies in optimal possible conditions.
The French healthcare giant is also committed to working with and supporting the investigators and patients included in the ongoing phase III studies, pending the definition of the terms of this transfer with Lexicon.
Copyright (c) 2019 CercleFinance.com. All rights reserved.